Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng… - Cancer research, 2021 - AACR
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …
被引用次数：43 相关文章

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

H Han, S Li, T Chen, M Fitzgerald… - Cancer …, 2021 - mdanderson.elsevierpure.com
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …

Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

H Han, S Li, T Chen, M Fitzgerald, S Liu… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
No targeted treatments are currently approved for HER2 exon 20 insertion-mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

H Han, S Li, T Chen, M Fitzgerald, S Liu… - Cancer …, 2021 - scholars.northwestern.edu
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …
[HTML] nih.gov

[HTML][HTML] Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng… - Cancer …, 2021 - ncbi.nlm.nih.gov
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …

Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.

H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng… - Cancer …, 2021 - europepmc.org
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …

Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.

H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng… - Cancer …, 2021 - europepmc.org
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …
[HTML] nih.gov

[HTML][HTML] Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng… - Cancer …, 2021 - ncbi.nlm.nih.gov
No targeted treatments are currently approved for HER2 exon 20 insertion-mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …